ArticleEndocrinology, diabetes & metabolism2026
Growth and Neurodevelopmental Outcomes of Children With Congenital Hypothyroidism Identified Through Dried Blood Spot Newborn Screening at a Tertiary Care Hospital in Pakistan.
Article in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCongenital hypothyroidism (CH) is the most common congenital endocrine disorder and a leading preventable cause of intellectual disability in children. Pakistan lacks a national NBS program, and CH incidence is estimated at 1:1000-1:600, higher than the global average. AKUH, Karachi, introduced DBS screening for CH in 2019. This study assessed outcomes in neonates screened between 1 April 2019 and 31 March 2024.
methodsNeonates with positive DBS (TSH > 10 μIU/mL) and confirmed CH (FT4 < normal and TSH > 20 μIU/mL) were included; growth and ASQ-3 records were extracted.
resultsAmong 53,799 screened babies, 971 were screened positive; of these, 40 (4.12%) were true positives. Thirty-nine neonates were included; 34 had ASQ-3 records. Females were n = 23 (59%); median gestational age was 38 weeks, 82.1% had normal birth weight, and median birth weight was 2.8 kg. DBS was performed after 36 h in 64.1%. Eight neonates were symptomatic; prolonged jaundice occurred in 20.51%; one had trisomy 21; and eight (20.5%) had a family history of hypothyroidism. At 3 years, weight SDS ranged from -2.02 to 0.98 and height SDS from -2.15 to 1.65, with median height SDS of -0.62. Global delay was observed in one child (3%), fine motor and personal-social impairment in one child each (3%) and normal development in 32 (94.1%).
conclusionsThe child with global delay was suspected to have an underlying neurometabolic disorder unrelated to CH. DBS screening at AKUH detected CH consistently with local estimates, and early treatment was associated with normal growth and neurodevelopment in most neonates at 2-year follow-up. These findings support NBS expansion in Pakistan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.